Guillain-Barre Syndrome Market (Therapeutics: Intravenous Immunoglobulin, Plasma Exchange, and Others; and Route of Administration: Oral and Parenteral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
길랭 바레 증후군 시장 - 보고서의 범위
TMR의 세계 길랭 바레 증후군 시장에 대한 보고서는 과거와 현재의 성장 동향과 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻을 수 있는 기회를 조사했습니다. 이 보고서는 전 세계 길랭 바레 증후군 수익을 제공합니다. 2023년을 기준 연도로, 2031년을 예측 연도로 간주하여 2017년부터 2031년까지의 기간 동안 밸리 증후군 시장을 분석했습니다. 이 보고서는 또한 2023년부터 2031년까지 세계 길랭 바레 증후군 시장의 복합 연간 성장률(CAGR%)을 제공합니다.
이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서는 분석가들이 주요 오피니언 리더, 업계 리더 및 오피니언 제조업체를 인터뷰하여 주요 연구 활동의 대부분을 수행했으며, 2차 조사에서는 길랭 바레 증후군 시장을 이해하기 위해 주요 기업의 제품, 연례 보고서, 보도 자료, 언론 보도, 보도자료 및 기타 문헌을 검토했습니다. 문헌, 연례 보고서, 보도 자료 및 관련 문서에 대한 참조가 포함됩니다.
| 시장 현황 |
| 2023년 시장 가치 |
5억 9,130만 달러 |
| 2031년 시장 가치 |
8억 9,020만 달러 |
| CAGR |
4.7% |
이 보고서는 세계 길랭 바레 증후군 시장의 경쟁 환경에 대해 자세히 조사했습니다. 세계 길랭 바레 증후군 시장에서 활동하는 주요 기업이 확인되었으며, 이들 각각은 다양한 속성 측면에서 프로파일링됩니다. 기업 프로파일, 재무 상태, 최근 동향 및 SWOT는 이 보고서에 소개된 세계 길랭 바레 증후군 시장의 기업 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
- 서론
- 개요
- 시장 역학
- 세계 시장 분석과 예측, 2017년-2031년
제5장 주요 인사이트
- 파이프라인 분석
- 주요 제품/브랜드 분석
- 주요 합병과 인수
- COVID-19 감염증 팬데믹이 업계에 미치는 영향
제6장 세계 시장 분석과 예측 : 치료별
- 서론과 정의
- 주요 조사 결과/발전
- 시장 매출 예측 : 치료별, 2017년-2031년
- 시장 매력 분석 : 치료별
제7장 세계 시장 분석과 예측 : 투여 경로별
- 서론과 정의
- 주요 조사 결과/발전
- 시장 매출 예측 : 투여 경로별, 2017년-2031년
- 시장의 매력 분석 : 투여 경로별
제8장 세계 시장 분석과 예측 : 유통 채널별
- 서론과 정의
- 주요 조사 결과/발전
- 시장 매출 예측 : 유통 채널별, 2017년-2031년
- 시장의 매력 분석 : 유통 채널별
제9장 세계 시장 분석과 예측 : 지역별
- 주요 조사 결과
- 시장 매출 예측 : 지역별, 2017년-2031년
- 북미
- 유럽
- 아시아태평양
- 남미
- 중동 및 아프리카
- 시장의 매력 분석 : 지역별
제10장 북미 시장 분석과 예측
제11장 유럽 시장 분석과 예측
제12장 아시아태평양 시장 분석과 예측
제13장 남미 시장 분석과 예측
제14장 중동 및 아프리카 시장 분석과 예측
제15장 경쟁 구도
- 시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
- 시장 점유율 분석 : 기업별(2022년)
- 기업 개요
- Grifols SA
- CSL Behring LLC
- Shire plc
- Octapharma AG
- Nihon Pharmaceutical Co.,Ltd
- Akari Therapeutics, PLC
- Biotest AG
- Kedrion SpA
LSH
Guillain-Barre Syndrome Market - Scope of Report
TMR's report on the global Guillain-Barre Syndrome market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Guillain-Barre Syndrome market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Guillain-Barre Syndrome market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Guillain-Barre Syndrome market.
| Market Snapshot |
|---|
| Market Value in 2023 | US$ 591.3 Mn |
| Market Value in 2031 | US$ 890.2 Mn |
| CAGR | 4.7% |
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Guillain-Barre Syndrome market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Guillain-Barre Syndrome market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Guillain-Barre Syndrome market.
The report delves into the competitive landscape of the global Guillain-Barre Syndrome market. Key players operating in the global Guillain-Barre Syndrome market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Guillain-Barre Syndrome market profiled in this report.
Key Questions Answered in Global Guillain-Barre Syndrome Market Report:
- What is the sales/revenue generated by Guillain-Barre Syndrome across all regions during the forecast period?
- What are the opportunities in the global Guillain-Barre Syndrome market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2031?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Guillain-Barre Syndrome Market - Research Objectives and Research Approach
The comprehensive report on the global Guillain-Barre Syndrome market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Guillain-Barre Syndrome market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Guillain-Barre Syndrome market.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Guillain-Barre Syndrome Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Guillain-Barre Syndrome Market Analysis and Forecast, 2017-2031
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Key Product/Brand Analysis
- 5.3. Key Mergers & Acquisitions
- 5.4. COVID-19 Pandemic Impact on Industry
6. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Therapeutics
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Therapeutics, 2017-2031
- 6.3.1. Intravenous Immunoglobulin
- 6.3.2. Plasma Exchange
- 6.3.3. Others
- 6.4. Market Attractiveness Analysis, by Therapeutics
7. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Route of Administration
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Route of Administration, 2017-2031
- 7.3.1. Oral
- 7.3.2. Parenteral
- 7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Distribution Channel
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 8.3.1. Hospitals
- 8.3.2. Pharmacies
- 8.3.3. Retail Pharmacies
- 8.3.4. Others
- 8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Region
- 9.1. Key Findings
- 9.2. Market Value Forecast, by Region, 2017-2031
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. South America
- 9.2.5. Middle East & Africa
- 9.3. Market Attractiveness Analysis, by Region
10. North America Guillain-Barre Syndrome Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Key Findings
- 10.3. Market Value Forecast, by Therapeutics, 2017-2031
- 10.3.1. Intravenous Immunoglobulin
- 10.3.2. Plasma Exchange
- 10.3.3. Others
- 10.4. Market Value Forecast, by Route of Administration, 2017-2031
- 10.4.1. Oral
- 10.4.2. Parenteral
- 10.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 10.5.1. Hospitals
- 10.5.2. Pharmacies
- 10.5.3. Retail Pharmacies
- 10.5.4. Others
- 10.6. Market Value Forecast, by Country, 2017-2031
- 10.6.1. U.S.
- 10.6.2. Canada
- 10.7. Market Attractiveness Analysis
- 10.7.1. By Therapeutics
- 10.7.2. By Route of Administration
- 10.7.3. By Distribution Channel
- 10.7.4. By Country
11. Europe Guillain-Barre Syndrome Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Key Findings
- 11.3. Market Value Forecast, by Therapeutics, 2017-2031
- 11.3.1. Intravenous Immunoglobulin
- 11.3.2. Plasma Exchange
- 11.3.3. Others
- 11.4. Market Value Forecast, by Route of Administration, 2017-2031
- 11.4.1. Oral
- 11.4.2. Parenteral
- 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 11.5.1. Hospitals
- 11.5.2. Pharmacies
- 11.5.3. Retail Pharmacies
- 11.5.4. Others
- 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.6.1. Germany
- 11.6.2. U.K.
- 11.6.3. France
- 11.6.4. Italy
- 11.6.5. Spain
- 11.6.6. Rest of Europe
- 11.7. Market Attractiveness Analysis
- 11.7.1. By Therapeutics
- 11.7.2. By Route of Administration
- 11.7.3. By Distribution Channel
- 11.7.4. By Country/Sub-region
12. Asia Pacific Guillain-Barre Syndrome Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Key Findings
- 12.3. Market Value Forecast, by Therapeutics, 2017-2031
- 12.3.1. Intravenous Immunoglobulin
- 12.3.2. Plasma Exchange
- 12.3.3. Others
- 12.4. Market Value Forecast, by Route of Administration, 2017-2031
- 12.4.1. Oral
- 12.4.2. Parenteral
- 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.5.1. Hospitals
- 12.5.2. Pharmacies
- 12.5.3. Retail Pharmacies
- 12.5.4. Others
- 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. China
- 12.6.2. Japan
- 12.6.3. India
- 12.6.4. Australia & New Zealand
- 12.6.5. Rest of Asia Pacific
- 12.7. Market Attractiveness Analysis
- 12.7.1. By Therapeutics
- 12.7.2. By Route of Administration
- 12.7.3. By Distribution Channel
- 12.7.4. By Country/Sub-region
13. South America Guillain-Barre Syndrome Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Key Findings
- 13.3. Market Value Forecast, by Therapeutics, 2017-2031
- 13.3.1. Intravenous Immunoglobulin
- 13.3.2. Plasma Exchange
- 13.3.3. Others
- 13.4. Market Value Forecast, by Route of Administration, 2017-2031
- 13.4.1. Oral
- 13.4.2. Parenteral
- 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.5.1. Hospitals
- 13.5.2. Pharmacies
- 13.5.3. Retail Pharmacies
- 13.5.4. Others
- 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. Brazil
- 13.6.2. Mexico
- 13.6.3. Rest of South America
- 13.7. Market Attractiveness Analysis
- 13.7.1. By Therapeutics
- 13.7.2. By Route of Administration
- 13.7.3. By Distribution Channel
- 13.7.4. By Country/Sub-region
14. Middle East & Africa Guillain-Barre Syndrome Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Key Findings
- 14.3. Market Value Forecast, by Therapeutics, 2017-2031
- 14.3.1. Intravenous Immunoglobulin
- 14.3.2. Plasma Exchange
- 14.3.3. Others
- 14.4. Market Value Forecast, by Route of Administration, 2017-2031
- 14.4.1. Oral
- 14.4.2. Parenteral
- 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 14.5.1. Hospitals
- 14.5.2. Pharmacies
- 14.5.3. Retail Pharmacies
- 14.5.4. Others
- 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.6.1. GCC Countries
- 14.6.2. South Africa
- 14.6.3. Rest of Middle East & Africa
- 14.7. Market Attractiveness Analysis
- 14.7.1. By Therapeutics
- 14.7.2. By Route of Administration
- 14.7.3. By Distribution Channel
- 14.7.4. By Country/Sub-region
15. Competition Landscape
- 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
- 15.2. Market Share Analysis, by Company (2022)
- 15.3. Company Profiles
- 15.3.1. Grifols S.A
- 15.3.1.1. Company Overview
- 15.3.1.2. Product Portfolio
- 15.3.1.3. SWOT Analysis
- 15.3.1.4. Financial Overview
- 15.3.1.5. Strategic Overview
- 15.3.2. CSL Behring LLC
- 15.3.2.1. Company Overview
- 15.3.2.2. Product Portfolio
- 15.3.2.3. SWOT Analysis
- 15.3.2.4. Financial Overview
- 15.3.2.5. Strategic Overview
- 15.3.3. Shire plc
- 15.3.3.1. Company Overview
- 15.3.3.2. Product Portfolio
- 15.3.3.3. SWOT Analysis
- 15.3.3.4. Financial Overview
- 15.3.3.5. Strategic Overview
- 15.3.4. Octapharma AG
- 15.3.4.1. Company Overview
- 15.3.4.2. Product Portfolio
- 15.3.4.3. SWOT Analysis
- 15.3.4.4. Financial Overview
- 15.3.4.5. Strategic Overview
- 15.3.5. Nihon Pharmaceutical Co.,Ltd
- 15.3.5.1. Company Overview
- 15.3.5.2. Product Portfolio
- 15.3.5.3. SWOT Analysis
- 15.3.5.4. Financial Overview
- 15.3.5.5. Strategic Overview
- 15.3.6. Akari Therapeutics, PLC
- 15.3.6.1. Company Overview
- 15.3.6.2. Product Portfolio
- 15.3.6.3. SWOT Analysis
- 15.3.6.4. Financial Overview
- 15.3.6.5. Strategic Overview
- 15.3.7. China Biological Products Holdings,Inc.
- 15.3.7.1. Company Overview
- 15.3.7.2. Product Portfolio
- 15.3.7.3. SWOT Analysis
- 15.3.7.4. Financial Overview
- 15.3.7.5. Strategic Overview
- 15.3.8. Biotest AG
- 15.3.8.1. Company Overview
- 15.3.8.2. Product Portfolio
- 15.3.8.3. SWOT Analysis
- 15.3.8.4. Financial Overview
- 15.3.8.5. Strategic Overview
- 15.3.9. Kedrion S.p.A
- 15.3.9.1. Company Overview
- 15.3.9.2. Product Portfolio
- 15.3.9.3. SWOT Analysis
- 15.3.9.4. Financial Overview
- 15.3.9.5. Strategic Overview
